NASDAQ: SLS · Health Care · Cancer drug developers

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor tambiciclib (SLS009).

Our rating
Sell
12-month target
$8.77
Price, Nov 17, 2026
$19.15
Expected return, with dividend
−54%

Latest research: initiation, Nov 19, 2026Market value $3,897.6m

SLSSellTarget $8.77−54% expected
Our SLS model 14 sheets: Summary, Thesis, Market Check, Assumptions, … · Updated Nov 19, 2026 Free to view Open the model
$19.15Price $8.7712-month target
Implied return -54% to our target. Bear to bull $0.18 to $26.77, from our initiation of Nov 19, 2026. We expect a total return worse than −10% over the next 12 months: a fall of more than 10%, after dividends.

Sum-of-programmes risk-adjusted NPV at an 11.06% cost of equity with zero terminal value: GPS CR2 ($3.03), GPS CR1 ($2.49) and SLS009 ($0.39) less corporate costs and tax, plus net cash, offering and future raises, gives a $4.97 base on 230.9m diluted shares. Bear, base and bull values of $0.18, $4.97 and $26.77 are weighted 30/50/20% to $7.90 and rolled forward 12 months to the $8.77 target. A 2.3x FY30E peer sales exit gives $4.11.

Bear case
$0.18
-99% from $19.15
  • Confirmatory study required
  • CR2 approval odds cut to 40%
  • Launch slips to FY29E
  • $200k US net price
Base case
$4.97
-74% from $19.15
  • 65% CR2 approval odds
  • $300k US net price
  • 45% CR2 uptake
  • FY28E launch
Bull case
$26.77
+40% from $19.15
  • 85% CR2 approval odds
  • $450k US net price
  • 70% CR2 uptake
  • 50% CR1 approval odds
Base rNPV per share
$4.97
Probability-weighted value
$7.90
Value at 100% CR2 approval odds
$6.36
Peer sales exit cross-check
$4.11
Cost of equity
11.06%
EV/FY30E sales
21.8x
Price-implied peak US GPS sales
$4,922.7m
Cash floor per share
$1.19

Our estimates

LineFY26EFY27EFY28E
Revenue$0m$0m$19m
Consensus$0m$53m$122m
Ours vs consensus—−100.0%−84.4%
EPS−$0.19−$0.48−$0.43
Consensus−$0.28——
Ours vs consensus+32.1%——

Sign in to Penmark